The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

被引:45
|
作者
Weiden, Peter J. [1 ]
Roma, Rebecca S. [2 ]
Velligan, Dawn I. [3 ]
Alphs, Larry [4 ]
DiChiara, Matthew [5 ]
Davidson, Brad [5 ]
机构
[1] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Schizophrenia & Related Disorders, San Antonio, TX 78229 USA
[3] Mercy Behav Hlth Pittsburgh, Community Treatment Team, Pittsburgh, PA USA
[4] Janssen Sci Affairs, Therapeut Area Lead Psychiat, Titusville, NJ USA
[5] Ogilvy CommonHlth Behav Insights, Parsippany, NJ USA
关键词
Antipsychotics; Delivery of Care; Schizophrenia; SHARED DECISION-MAKING; IN-OFFICE; PERSPECTIVES; ADHERENCE; DEPOT; COMMUNICATION; PERCEPTIONS; STRATEGIES; ATTITUDES; PROVIDER;
D O I
10.4088/JCP.13m08946
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To characterize patterns of communication in the offer of long-acting injectable (LAI) antipsychotic medication made by psychiatrists to patients with schizophrenia by (1) examining the style and content of their interaction and (2) determining how these may have driven the ultimate response to recommendations for LAI therapy. Method: This was an observational study conducted at 10 community mental health centers in 3 waves from July 2010 to May 2011. The final dataset for discourse analysis was 33 recorded conversations in which a psychiatrist offered an injectable antipsychotic to a patient with schizophrenia. These visits were transcribed and analyzed by a team of linguists and social scientists. Results: Our primary finding is that, based on analyses of their language during the interview, psychiatrists presented LAI therapy in a negative light. Supporting this, 11 of 33 recommendations (33%) were accepted during the discussion, whereas in the postvisit interview, 27 of 28 patients (96%) who seemed to decline the initial recommendation said they actually would be willing to try LAI treatment. Conclusions: These data support a preliminary hypothesis that the relatively low use of injectable antipsychotic therapies in the United States relative to other parts of the world is not fully attributable to patient rejection of the injectable modality. Rather, psychiatrists' ambivalence regarding the value of LAIs may play a significant role in the perceived difficulty with patient acceptance of this recommendation. (c) Copyright 2015 Physicians Postgraduate Press, Inc.
引用
收藏
页码:684 / 690
页数:7
相关论文
共 50 条
  • [31] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Kim, H.
    Hong, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S456
  • [32] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Ciwoniuk, M.
    Godlewska, B. R.
    Olajossy-Hilkesberger, L.
    Olajossy, M.
    Marmurowska-Michalowska, H.
    Limon, J.
    Landowski, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S457
  • [33] Efficacy and safety of long-acting injectable risperidone in patients with schizophrenia
    Bouhours, P
    Schreiner, A
    Rendall, MR
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 170 - 171
  • [34] Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 212S - 212S
  • [35] EFFECTIVENESS OF A LONG-ACTING INJECTABLE ANTIPSYCHOTIC IN FIRST-EPISODE SCHIZOPHRENIA: THE EONKCS STUDY
    Chiliza, Bonginkosi
    Asmal, Laila
    Emsley, Robin
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S305 - S306
  • [36] Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 198 - 198
  • [37] Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia
    Karlovic, Dalibor
    Silic, Ante
    Crnkovic, Danijel
    Peitl, Vjekoslav
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2021, 36 (02)
  • [38] Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
    Citrome, Leslie
    Belcher, Emily
    Stacy, Sylvie
    Suett, Mark
    Mychaskiw, Marko
    Salinas, Gregory D.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 111 - 123
  • [39] EVALUATION OF PALIPERIDONE PALMITATE LONG-ACTING INJECTABLE THERAPY BY DURATION OF ILLNESS IN PATIENTS WITH SCHIZOPHRENIA
    Brown, B.
    Turkoz, I.
    Mancevski, B.
    Mathews, M.
    Reeve-Parker, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 : 161 - 161
  • [40] Barriers to long-acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey
    Oguchi, Yoshiyo
    Miyake, Nobumi
    Ando, Kumiko
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2024, 44 (02) : 417 - 423